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nil.dhaneshwar@gAbstract The objective of current study was to develop a validated speciﬁc stability indicating
reversed-phase liquid chromatographic method for the quantitative determination of desvenlafax-
ine in bulk sample and pharmaceutical dosage form in the presence of degradation products.
Forced degradation studies were performed on bulk sample of desvenlafaxine as per ICH
prescribed stress conditions using acid, base, oxidative and photolytic degradation to show the
stability indicating power of the method. Signiﬁcant degradation was observed under acidic stress
condition and the degradation product formed was identiﬁed by LC–MS and a degradation
pathway for drug has been proposed. Successful separation of drug from degradation products
formed under stress conditions was achieved on a SymmetryShield column C18 (5 mm,
250 mm 4.6 mm, i.d.) using the mobile phase consisting of a mixture of 0.2% (v/v) triethylamine
in ammonium acetate (0.05 M; pH 6.5) and methanol using isocratic gradient.
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Desvenlafaxine, the major active metabolite of venlafaxine, is used
in the treatment of depression. Chemically it is 4-[2-(dimethyla-
mino)-1-(1-hydroxycyclohexyl) ethyl] phenol (Fig. 1). Desvenla-
faxine is a selective serotonin and norepinephrine reuptake
inhibitor [1–3]. Literature review reveals that methods have been
reported for analysis of venlafaxine by UV spectrophotometry [4]
and HPLC [5,6], identiﬁcation of desvenlafaxine by HPLC [7],
estimation of venlafaxine by stability-indicating HPLC [8,9],
determination of venlafaxine and its three metabolites in human
plasma by HPLC–MS/ESI [10,11], analysis of venlafaxine meta-
bolites in rat liver by chiral HPLC [12] and analysis of venlafaxine
in tablet by HPTLC [13].
Figure 1 Structure of desvenlafaxine.
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behavior of desvenlafaxine under various ICH prescribed
stress conditions has been lacking. So we decided to carry
out forced degradation studies according to the ICH require-
ments and develop a selective and validated stability-indicat-
ing HPLC method. An integral aim of the study was to
identify degradation products and to postulate complete
degradation pathway of the drug. The International Confer-
ence on Harmonization (ICH) guideline entitled Stability
Testing of New Drug Substances and Products requires testing
to be performed to elucidate the inherent stability character-
istics of the active substance [14]. The proposed method was
validated according to ICH guidelines [15] and its updated
international convention.2. Experimental
2.1. Materials
Dr. Reddy’s Laboratories Ltd. (Hyderabad, Andhra Pradesh,
India), kindly supplied pure drug sample of desvenlafaxine as
a gift sample of Batch no.: ADWSP092. Twenty tablets of
desvenlafaxine (Brand name: D-VENIZ label claim: 50 mg
desvenlafaxine per tablet, Batch no.: SKK0179, Expiry date:
November 2012) were procured from a local Pharmacy in
Pune, Maharashtra, India. All chemicals and reagents used
were of analytical grade and purchased from Merck Chemi-
cals, Mumbai, Maharashtra, India.2.2. Instrumentation
The LC system included a Jasco Inc. (Easton, MD) Model PU
2080 Intelligent LC Pump with sampler programmed at 20 mL
injection and a UV detector (Jasco Model UV 2075) operated
at a wavelength of 228 nm. Data were integrated using the Jasco
Borwin Version 1.5, LC-Net II/ADC system. The column used
was SymmetryShield column C18 (5 mm, 250 mm 4.6 mm i.d.)
from Waters, Milford, USA.
LC–MS studies were carried out on a 4000 Q-TRAP Linear
Ion Trap Quadrupole Mass Spectrometer (Applied Biosystems
Sciex, USA). The mass spectra of desvenlafaxine and the
degradation product were taken in ESI (Turbo Ion Spray) positive
mode in mass range of 40–600 amu and analyzed in the triple
quadrupole analyzer. Samples were dissolved in methanol in a
concentration range of 60 mg/mL and injected into the inlet. The
whole process was controlled using an Analyst 1.4.2 software. The
LC system attached to the MS was an Ultimate 3000 RS HPLC
system with an Ultimate 3000 RS pump, Ultimate 3000 RS
autosampler and Ultimate 3000 RS column compartment (Dio-
nex, CA, USA) and data were integrated using a Chromeleon v6.8 SR10 operating software. The mobile phase used was a
mixture of 0.2% (v/v) triethylamine in ammonium acetate
(0.05 M; pH 6.5) and methanol (40:60) and the column used
was C18 (5 mm, 250 mm 4.6 mm i.d.) from Waters, Milford,
USA. The ﬂow rate was 1 mL/min and the efﬂuent from the
column was introduced into the mass spectrometer through a ﬂow
splitter which splits volume of mobile phase and deliver minimum
amount of mobile phase in MS. The split ratio was 20:80.
2.3. Forced degradation studies
A stock solution (1 mg/mL) containing 100 mg desvenlafaxine
in 100 mL methanol was prepared. This solution was used for
forced degradation to provide an indication of the stability
indicating property and speciﬁcity of proposed method. In all
degradation studies, the average peak area of desvenlafaxine
(60 mg/mL) after application of seven replicates was obtained.
2.3.1. Acid and base induced degradation
Acid decomposition studies were performed by reﬂuxing the
solution of drug in 1 M HCl at 80 1C for 8 h. The studies
under alkaline conditions were performed in 5 M NaOH and
the solution was reﬂuxed for 8 h at 80 1C. The resultant
solutions were diluted to a concentration of 60 mg/mL and
20 mL was injected into the LC system.
2.3.2. Hydrogen peroxide induced degradation
To study hydrogen peroxide induced degradation, initial
studies were performed in 3% hydrogen peroxide at room
temperature for 24 h. Then drug was exposed to 6% hydrogen
peroxide at room temperature (2572 1C) for a period of 8 days
and then heated in a boiling water bath for 10 min to
completely remove the excess hydrogen peroxide. The resultant
solutions were diluted to obtain a concentration of 60 mg/mL
and 20 mL was injected into the LC system.
2.3.3. Photochemical degradation
The photochemical stability of the drug was studied by exposing
the stock solution (1000 mg/mL) to direct sunlight (60,000–
70,000 lx) for 15 days on a wooden plank kept on a terrace.
The photochemical stability of the drug was also performed
by keeping the stock solution (1000 mg/mL) in the stability
chamber (light providing an overall illumination of 1.2 million
lx h and an integrated near ultraviolet energy of not less than
200 W h/m2) for 15 days.
The solution was diluted with methanol to obtain a
concentration of 60 mg/mL and then 20 mL of the solution
was injected into the LC system.
2.4. Optimization of stability-indicating HPLC method
The HPLC procedure was optimized with a view to develop the
stability-indicating assay method. The pure drug along with its
degraded products was injected and run in different solvent
systems. Initially methanol and water in different ratios were
tried. It was found that when methanol concentration was
increased in the mobile phase, the pure drug started to elute in
dead volume. Hence the concentration of methanol was
decreased and there was improvement in resolution. It was
found that a mixture of 0.2% (v/v) triethylamine in ammonium
acetate (0.05 M; pH adjusted to 6.5 with glacial acetic acid) and
S.M. Pawar et al.266methanol (40:60) as a mobile phase at a ﬂow rate of 1 mL/min
gave acceptable retention time (tR), theoretical plates and good
resolution of the drug and degradation products (Fig. 2A and B).
2.5. Validation of the method
Validation of the optimized LC method was done with respect
to following parameters.
2.5.1. Linearity and range
Linearity of the method was studied by injecting seven
concentrations of the drug prepared in the mobile phase in
the range of 10–80 mg/mL in triplicate into the HPLC system
keeping the injection volume constant. The peak areas were
plotted against the corresponding concentrations to obtain the
calibration graphs.
2.5.2. Precision
Precision of the method was veriﬁed by repeatability and
intermediate precision studies. Repeatability studies were
performed by analysis of three different concentrations (10,
40, and 80 mg/mL) of the drug in hexaplicate (n¼6) on the
same day. Intermediate precision of the method was checked
by repeating studies on three different days.Figure 2 (A) Chromatogram of standard desvenlafaxine. Peak 1, tR:
ammonium acetate (0.05 M; pH adjusted to 6.5 with glacial acetic ac
product. Condition: 1 M HCl at 80 1C for 8 h. (Peak 1): desvenlafaxi2.5.3. Limit of detection (LOD) and limit of quantitation
(LOQ)
The signal to noise ratio was determined. LOD was considered
as 3:1 and LOQ as 10:1. The LOD and LOQ were experi-
mentally veriﬁed by diluting known concentrations of stan-
dard solution of desvenlafaxine until the average responses
were approximately 3 or 10 times the standard deviation of the
responses for six replicate determinations.2.5.4. Robustness of the method
To evaluate robustness of the HPLC method, few parameters
were deliberately varied. The parameters included variation
of ﬂow rate, percentage of methanol in the mobile phase, pH
of mobile phase. Robustness of the method was done at
three different concentration levels 10, 40, and 80 mg/mL for
desvenlafaxine.2.5.5. Speciﬁcity
The speciﬁcity of the method towards the drug was established
through study of resolution factor of the drug peak from the
nearest resolving peak. Overall selectivity was established
through determination of purity for each degradation product
peak using PDA detector.3.60 min. Mobile phase: a mixture of 0.2 % (v/v) triethylamine in
id) and methanol (40:60). (B) Chromatogram of acid degradation
ne, tR: 3.63 min. (Peak 2): degraded, tR: 4.87 min.
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To determine the content of desvenlafaxine in conventional tablets
(Brand name: D-VENIZ, Sun Pharmaceuticals Industries Ltd.,
Batch no. SKK0179, label claim: 50 mg desvenlafaxine per tablet,
expiry date: November 2012), the contents of 20 tablets were
weighed, their mean weight determined and ﬁnely powdered. An
equivalent weight of the powder/triturate was transferred to a
50 mL volumetric ﬂask containing 10 mL methanol, sonicated for
30 min and diluted to 50 mL with methanol. The resulting
solution was centrifuged at 3000 rpm for 5 min. Supernatant
was taken and after suitable dilution the sample solution was
then ﬁltered using a 0.45 mm ﬁlter (Millipore, Milford, MA). The
above stock solution was further diluted to get sample solution at
three different concentrations of 10, 40, and 80 mg/mL. A 20 mL
volume of each sample solution was injected into the LC system,
six times, under the conditions described above. The peak areas
were measured at 228 nm and concentrations in the samples were
determined using multilevel calibration developed on the same LC
system under the same conditions using linear regression equation.
2.5.7. Accuracy
Accuracy of the developed method was determined by applying
the method to a drug sample (desvenlafaxine tablets) to which a
known amount of desvenlafaxine standard powder corresponding
to 80%, 100%, and 120% of label claim was added (standard
addition method). The percentage recoveries were calculated from
the slope and Y-intercept of the calibration curve.3. Results and discussion
3.1. Results of forced degradation studies
3.1.1. Acid induced degradation product
The drug was found to be highly labile to acidic degradation
as compared to that of alkali. Initially 0.1 M hydrochloric acid
was used at 80 1C for 8 h but negligible degradation was
observed hence the strength of acid was increased, 10–20%
degradation was observed by heating drug solution with 1 M
hydrochloric acid at 80 1C for 8 h and associated with rise in a
major degradation product at retention time 4.87 min in
HPLC (Fig. 2B).
3.1.2. Base induced degradation product
Initially 1 M and 2 M sodium hydroxide solutions were used
at 80 1C for 8 h but no degradation was observed hence the
strength of alkali was increased. Subsequently, studies were
performed in 5 M sodium hydroxide which was reﬂuxed at
80 1C for 8 h. It was found that the drug was highly stable to
alkali condition.
3.1.3. Hydrogen peroxide induced degradation product
In 6% hydrogen peroxide at room temperature the drug was
found to be stable to degradation as negligible degradation was
seen after exposing drug to 6% hydrogen peroxide for 8 days.
3.1.4. Photochemical degradation product
The drug was found to be stable against photochemical
degradation as negligible degradation was seen after exposing
the drug solution to direct sunlight as well as in photo-stability
chamber for 15 days.3.2. Identiﬁcation of major degradation product formed under
acidic stress condition
LC–MS analysis was carried out for the acid stress sample of
desvenlafaxine using a 4000 Q-TRAP Linear Ion Trap Quadru-
pole Mass Spectrometer with suitable volatile buffer ammonium
acetate (0.05 M, pH 6.5) as mobile phase. Satisfactory separation
of degradation product was achieved using a C18 column. The
degradation product formed shows the m/z of 246.5 which has 18
lesser m/z value than desvenlafaxine m/z 264.4 (Fig. 3). The
fragmentation for the degradant was also carried out for
degradation product and desvenlafaxine using product ion scan
by LCMS/MS. Based on the molecular weight and the fragmen-
tation pattern, the presence of degradation product was con-
ﬁrmed and also, the structure could be proposed. The
fragmentation pattern (Fig. 4) clearly indicates that there is
one possible structure of degradation product formed under
acidic condition. The fragment 246.5 formed from the cleavage
of –OH bond attached to cyclohexane ring and loss of water
molecule (m/z 18). So the probable structure is 4-[2-(dimethyla-
mino)(1-cyclohexylidene) ethyl]phenol as shown in Fig. 5.
3.3. Results of method validation
The results of validation studies on the stability-indicating
method developed for desvenlafaxine in the current study
involving a mixture of 0.2% (v/v) triethylamine in ammonium
acetate (0.05 M; pH adjusted to 6.5 with glacial acetic acid)
and methanol (40:60) as a mobile phase are given below.
3.3.1. Linearity
The response for the drug was linear in the concentration range
of 10-80 mg/mL. The mean (7RSD) values of slope, intercept
and correlation coefﬁcient were 8658.1 (71.30), 21789 (71.57)
and 0.9998 (70.876), respectively.
3.3.2. Precision
The results of the repeatability and intermediate precision
experiments are shown in Table 1. The developed method was
found to be precise as the RSD values for repeatability and
intermediate precision studies were o2%, respectively, as
recommended by ICH guideline. Separation of the drug and
degradation product in stressed sample was found to be
similar when analysis was performed on different chromato-
graphic systems on different days.
3.3.3. LOD and LOQ
The signal:noise ratios of 3:1 and 10:1 were considered as
LOD and LOQ, respectively. The LOD and LOQ were found
to be 5 mg/mL and 10 mg/mL, respectively.
3.3.4. Robustness of the method
Each factor selected (except columns from different manufac-
turers and solvents of different lots) was changed at three
levels (1, 0 and 1). One factor at a time was changed to
estimate the effect. Thus, replicate injections (n¼6) of mixed
standard solution at three concentration levels were performed
under small changes of three chromatographic parameters
(factors). Insigniﬁcant differences in peak areas and less varia-
bility in retention time were observed (Table 2).
Figure 3 Representative positive ESI-Quadrupole (þQ1) mass spectra of desvenlafaxine and acid degradation product.
Figure 4 Fragmentation mass spectrum of degradation product formed in acidic degradation of desvenlafaxine.
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The speciﬁcity of the LC method is illustrated in Fig. 3, where
complete separation of desvenlafaxine in the presence of its
degradation product was seen. The peaks obtained were sharpand had clear baseline separation. The resolution factor for
the drug from its nearest peak was 43 (Fig. 2B). The
photodiode array detector scanned all of the components
present in a mixture in the wavelength range from 200 to
Figure 5 Structure of degradation product (m/z: 246.5) formed in acidic degradation of desvenlafaxine.
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Table 1 Precision studies for desvenlafaxine.
Concentration
(mg/mL)
Intra-day precision (n¼6) Inter-day precision (n¼6)
Measured
concentration
(mg/mL)
RSD
(%)
Recovery
(%)
Measured
concentration
(mg/mL)
RSD
(%)
Recovery
(%)
10 9.87 1.13 98.70 9.89 0.23 98.90
40 39.92 1.01 99.80 40.01 0.03 100.02
80 78.99 1.22 98.73 79.88 0.38 99.85
Table 2 Robustness testing for desvenlafaxinea (n¼6).
Factorb Level tR
c kd Te
Flow rate (mL/min)
0.9 1 3.71 1.62 1.20
1.0 0 3.60 1.75 1.01
1.1 þ1 3.47 2.04 1.11
Mean7SD 3.5970.12 1.8070.21 1.8070.09
Percent of methanol
in the mobile phase (v/v)
59 1 3.70 2.40 0.98
60 0 3.60 2.89 1.24
61 þ1 3.61 1.23 1.13
Mean7SD 3.6370.05 2.1770.85 1.11670.13
pH of mobile phase
6.4 1 3.32 2.45 1.23
6.5 0 3.60 2.87 1.02
6.6 þ1 3.67 2.99 1.01
Mean7SD 3.5370.18 2.7770.28 1.0870.12
aAverage of three concentrations: 10, 40 and 80 mg/mL.
bThree factors were slightly changed at three levels (1, 0,
and þ1).
ctR¼retention time (min).
dk¼retention factor.
eT¼ tailing factor.
Table 3 Analysis of commercial formulation (D-VENIZ,
50 mg) (n¼6).
Commercial
formulation
D-VENIZ (50 mg)
Drug found
(mean7SD, mg)
Recovery
(mean7SD, %)
1st lot 50.0970.17 100.1870.21
2nd lot 49.9170.55 99.8270.49
Table 4 Accuracy (% recovery) of desvenlafaxine in tablet
formulation at three concentration levels (n¼6).
Label
claim
(mg per
tablet)
Amount
added (%)
Total
amount
(mg)
Amount
recovered
(mg)7RSD
(%)
Recovery
(%)
50 80 90 89.2170.12 99.12
100 100 98.9070.11 98.90
120 110 110.2070.11 100.18
S.M. Pawar et al.270400 nm. Results indicated that there were no degradation peak
hiding under, or unresolved from the analyte peak (pure drug),
which also reﬂected the speciﬁcity of the method.
3.3.6. Analysis of marketed formulation
Two different lots of commercially available desvenlafaxine
tablet were analyzed using the proposed procedures and the
results are summarized in Table 3.
3.3.7. Recovery studies
As shown from the data in Table 4 good recoveries of the drug
in the range from 98.9% to 100.18% were obtained at various
added concentrations.4. Conclusion
In this paper a sensitive, speciﬁc, accurate, validated and well-
deﬁned stability indicating LC method for the determinationof desvenlafaxine in the presence of degradation product was
described. The behavior of desvenlafaxine under various stress
conditions was studied; the acid degradants were identiﬁed by
LC–MS. The drug was found to be stable in basic, oxidative
and photolytic conditions. The degradation product was well
separated from the drug substance demonstrating the stability
indicating capability of the method. The method was validated
for parameters like linearity, precision, accuracy, speciﬁcity,
etc. and was also applied to real marketed samples. The
information presented herein could be very useful for quality
monitoring of bulk samples and also employed to check the
quality of drug during stability studies.
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